Jazz Pharmaceuticals plc 8-K

What Happened On February 24, 2026, Jazz Pharmaceuticals plc announced its financial results for the fourth quarter and full year ended December 31, 2025 in a press release. The company furnished that press release as Exhibit 99.1 to a Form 8‑K (Item 2.02) filed the same day reporting results of operations and financial condition.

Key Details

• Press release date: February 24, 2026 (furnished as Exhibit 99.1 to the Form 8‑K).
• Reporting periods: fourth quarter and full year ended December 31, 2025.
• Form 8‑K items: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
• Filing signed by Philip L. Johnson, Executive Vice President and Chief Financial Officer, on February 24, 2026.

Why It Matters This filing notifies investors that Jazz has publicly released its latest earnings and operational results for Q4 and full-year 2025. The 8‑K itself furnishes the press release but does not include the numerical details in the filing text — investors should review Exhibit 99.1 (the press release) or the company’s investor relations materials for specific figures on revenue, earnings, guidance, and other metrics that could affect valuation and near‑term trading decisions. Keywords: earnings, revenue, quarterly results, financial results.